首页> 外文期刊>Perspectives in Clinical Research >Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot
【24h】

Evaluation of treatment outcome and adverse drug reaction of directly observed treatment (DOT) plus regimen in multidrug-resistant tuberculosis (MDR-TB) patients at district tuberculosis centre Rajkot

机译:在拉杰果德地区结核病中心对耐多药结核病(MDR-TB)患者进行直接观察治疗(DOT)加方案的治疗结果和药物不良反应评估

获取原文
       

摘要

Background: The emergence of drug-resistant mycobacteria becomes a significant public health problem globally creating an obstacle to effective tuberculosis (TB) control. Gujarat, Maharashtra, and Andhra Pradesh DRS survey estimated that the proportion of multidrug-resistant TB (MDR-TB) is 2.1% (in new TB cases) and 15% (in previously treated cases). Programmatic management of MDR-TB implemented under Revised National Tuberculosis Control Programme in India in 2007. Objectives: The objective of this study is to evaluate treatment outcome and adverse drug reactions (ADRs) of category IV. Materials and Methods: A total of 108 MDR-TB patients were analyzed retrospectively who registered and received treatment during the year of 2014 and 2015 at district TB centre, Rajkot. MDR patients who died or transferred out or defaulter before completion of intensive phase were excluded from the analysis. Results: Of total 108 patients majority patients (64.81%) were in young (20–39 years) with m:f: 2:1. All MDR-TB patients were retreated cases and 69.44% were “undernutrition category”. Culture conversion rate was 86.91% at 4 months of treatment. Cure rate was 50.93% while defaulter rate and died rate was same (17.59%). Failure rate was 18.51%. Weight improvement was significantly associated with cure rate. The incidence of ADR was 32.71%. Most frequent ADRs were related to gastrointestinal system (34.42%), ototoxicity (13.11%), and central nervous system (8.1%). Aminoglycosides, cycloserine, and ethambutol were discontinued due to ADR. Majority ADRs (77.04%) were “possible” category by causality assessment and “mild” in severity assessment. Ototoxicity was only severe ADRs observed. Conclusion: Cure rate was improved than previous years at same center. Attention should be paid for defaulters.
机译:背景:耐药性分枝杆菌的出现已成为全球范围内的重要公共卫生问题,为有效控制结核病(TB)提供了障碍。古吉拉特邦,马哈拉施特拉邦和安得拉邦DRS调查估计,耐多药结核病(MDR-TB)的比例为2.1%(在新的结核病病例中)和15%(在先前治疗的病例中)。 2007年在印度经修订的《国家结核病控制规划》下实施了耐多药结核病的程序化管理。目标:本研究的目的是评估第四类的治疗结果和药物不良反应(ADR)。材料与方法:回顾性分析了2014年和2015年在拉杰果德(Rajkot)结核病中心登记并接受治疗的108例耐多药结核病患者。在强化阶段完成之前死亡,转移或缺席的MDR患者被排除在分析之外。结果:在总共108例患者中,多数患者(64.81%)处于m:f:2:1的年轻(20-39岁)。所有耐多药结核病患者均接受了治疗,其中69.44%为“营养不良类别”。治疗4个月时的培养转化率为86.91%。治愈率为50.93%,违约率和死亡率是相同的(17.59%)。失败率为18.51%。体重减轻与治愈率显着相关。 ADR的发生率为32.71%。最常见的ADR与胃肠道系统(34.42%),耳毒性(13.11%)和中枢神经系统(8.1%)有关。氨基糖苷类,环丝氨酸和乙胺丁醇因ADR而停用。多数ADR(77.04%)在因果关系评估中为“可能”类别,在严重度评估中为“轻度”类别。耳毒性仅是观察到的严重ADR。结论:同一中心的治愈率比往年有所提高。应注意违约者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号